title: Treatment of malignant lymphomas with very-high-dose CVB followed by transplantation of autologous blood stem cells collected after mobilizing chemotherapy.
abstract: In 8 patients (age 25 +/- 46 years, mean 34.5), 4 with Hodgkin's disease (HD) and 4 with non-Hodgkin's lymphoma (NHL), circulating stem cells (CSC) collected at the time of rapid leukocyte and platelet recovery after intense chemotherapy were employed for autologous hematological reconstitution after very-high-dose chemotherapy (CVB combination). At the time of graft 2 patients were in 1st remission and 2 in 2nd, while the remaining 4 had persistence or progression of disease. Autografted patients received 3.4 +/- 8.3 (mean 5.2) x 10e8/Kg mononuclear cells and 2.1 +/- 40.5 (mean 22.5) x 10e4/Kg CFU-GM. All patients had prompt and sustained engraftment, though in one case platelets never reached normal levels. Recovery time was respectively 10 +/- 17 days (mean 13.2) for granulocytes 0.5 x 10e9/L, and 10 +/- 49 days (mean 20.3) for platelets greater than 50.0 x 10e9/L, with an interval of less than 4 days from greater than 0.5 to greater than 1.0 granulocytes in 7 out of the 8 patients. All patients are currently alive at 57 +/- 645 (median 262) days, and 7 in remission at 61 +/- 645 (median 297) days from autologous blood stem cell transplantation (ABSCT). Our study demonstrates that CSC collected after mobilizing chemotherapy are able to promptly restore and sustain hemopoiesis after marrow ablative chemotherapy in patients with malignant lymphoma. CSC reduce toxicity and hospitalization so impressive, that in malignant lymphomas ABSCT could rapidly be considered for first line strategy.
authors.affiliation: Divisione di Ematologia, Ospedale V. Cervello, Palermo, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Majolino
authors.forename: R
authors.initials: R
authors.lastname: Scimè
authors.forename: A
authors.initials: A
authors.lastname: Indovina
authors.forename: S
authors.initials: S
authors.lastname: Vasta
authors.forename: C
authors.initials: C
authors.lastname: Patti
authors.forename: S
authors.initials: S
authors.lastname: Gentile
authors.forename: A
authors.initials: A
authors.lastname: Santoro
authors.forename: R
authors.initials: R
authors.lastname: Di Noto
authors.forename: F
authors.initials: F
authors.lastname: Fabbiano
authors.forename: C
authors.initials: C
authors.lastname: Guarnaccia
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000494:pharmacology; D005047:Etoposide / Q000494:pharmacology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007937:Leukapheresis; D008223:Lymphoma / Q000188:drug therapy* / Q000628:therapy; D008875:Middle Aged; D010198:Pancytopenia / Q000139:chemically induced / Q000628:therapy; D011658:Pulmonary Fibrosis / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects; D012074:Remission Induction; D014182:Transplantation, Autologous; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin; D014751:Vindesine